Sanofi (NASDAQ:SNY) Shares Bought by Argonautica Private Wealth Management Inc.

Argonautica Private Wealth Management Inc. boosted its position in shares of Sanofi (NASDAQ:SNY) by 16.6% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 6,481 shares of the company’s stock after buying an additional 925 shares during the period. Argonautica Private Wealth Management Inc.’s holdings in Sanofi were worth $313,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. Allspring Global Investments Holdings LLC raised its position in Sanofi by 434.4% in the third quarter. Allspring Global Investments Holdings LLC now owns 50,583 shares of the company’s stock worth $2,915,000 after acquiring an additional 41,117 shares in the last quarter. Private Advisor Group LLC boosted its position in Sanofi by 2.6% during the third quarter. Private Advisor Group LLC now owns 52,338 shares of the company’s stock worth $3,016,000 after acquiring an additional 1,339 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Sanofi during the 3rd quarter valued at about $7,038,000. Allworth Financial LP raised its position in shares of Sanofi by 7.5% in the 3rd quarter. Allworth Financial LP now owns 5,081 shares of the company’s stock worth $293,000 after buying an additional 355 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its position in Sanofi by 21.8% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 11,721 shares of the company’s stock valued at $676,000 after buying an additional 2,100 shares in the last quarter. Hedge funds and other institutional investors own 14.04% of the company’s stock.

Wall Street Analysts Forecast Growth

SNY has been the topic of several recent analyst reports. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research note on Thursday, January 30th. StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Finally, Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $60.00.

Sanofi Price Performance

Shares of SNY stock opened at $54.89 on Wednesday. The firm’s 50 day moving average is $51.22 and its 200-day moving average is $52.56. Sanofi has a 1 year low of $45.22 and a 1 year high of $58.97. The firm has a market capitalization of $139.30 billion, a price-to-earnings ratio of 22.04, a PEG ratio of 1.01 and a beta of 0.57. The company has a current ratio of 1.46, a quick ratio of 1.14 and a debt-to-equity ratio of 0.15.

Sanofi (NASDAQ:SNY) last announced its earnings results on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. Sell-side analysts forecast that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.